StemCyte's Groundbreaking RegeneCyte® Program Receives FDA Clearance for Long COVID Patients StemCyte, Inc. announces FDA clearance for their Expanded Access program that allows Long COVID patients to access RegeneCyte®, a promising new therapy.

StemCyte's Groundbreaking RegeneCyte® Program Receives FDA Clearance for Long COVID Patients #United_States #StemCyte #REGENECYTE #Baldwin_Park #Long_COVID

FDA Greenlights StemCyte's REGENECYTE for Cord Blood Cell Therapy, Ushering in New Possibilities StemCyte's REGENECYTE™ Cord Blood Cell Therapy receives FDA approval, marking a pivotal moment for regenerative medicine and expanding treatment options for blood disorders.

FDA Greenlights StemCyte's REGENECYTE for Cord Blood Cell Therapy, Ushering in New Possibilities #United_States #StemCyte #REGENECYTE #FDA_Approval #Baldwin_Park